SESSION TITLE: Student/Resident Case Report Poster - Cardiovascular Disease I
SESSION TYPE: Student/Resident Case Report Poster
PRESENTED ON: Tuesday, October 25, 2016 at 01:30 PM - 02:30 PM
INTRODUCTION: Nivolumab a monoclonal antibody which selectively inhibits programmed cell death-1(PD-1) receptor is FDA approved for the treatment of solid cancers.1 We present a case of a 79 year old male with history of metastatic non small cell lung cancer (NSCLC) on nivolumab who presented with muscle pain, weakness and dyspnea. His presentation was consistent with nivolumab induced auto-immune myositis and myocarditis.